Pharmacokinetics of ofloxacin in patients with multidrug-resistant tuberculosis

Seung Kyu Park, Young Ran Yoon, Woo Chul Lee, Hyung Min Jun, Ji Hong Shon, Kyoung Ah Kim, Ji-Young Park, Jae Gook Shin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: There are few studies that have reported on the pharmacokinetic(PK) disposition of fluoroquinolones in patients with multi-drug resistant tuberculosis (MDR-Tb), even though fluoroquinolones are frequently co-prescribed to those patients. In this study, the PK disposition of ofloxacin, a fluoroquinolone, was evaluated in patients with MDR-Tb. Methods: Twenty patients with MDR-Tb were given 2nd line Tb drugs including ofloxacin (300mg twice a day), prothionamide, cycloserine, para-aminosalicylic acid, kanamycin, and streptomycin. The patients were grouped according to their body mass index(BMI) as an index of emaciation (group A: 18.5≤BMI<23, group B: BMI<18.5). Blood samples were serially drawn and urine samples were collected upto 24 hours after the last dose of those drugs at steady state (over 1 month). The ofloxacin concentrations were determined using HPLC (High Performance Liquid Chromatography). Results: The AUC of ofloxacin in group B was greater than that in group A (31.4±8.9μg/ml·h vs. 24.1± 6.2μg/ml·h) (Check the symbols), (p<0.05). The total clearance (Cl/F) of ofloxacin was 0.16±0.03 L/h/kg in group A, and 0.14±0.03 L/h/kg in group B. The half-lives of ofloxacin in two groups were similar (group A: 5.3±0.8 hours, group B: 5.7±0.9 hours). In addition, the other PK parameters in two groups were also similar. Conclusions: The pharmacokinetics of ofloxacin in patients with MDR-Tb appears to be comparable with those of normal subjects, and the extent of emaciation appears to have an influence on the pharmacokinetics of ofloxaicn in chronic debilitated MDR-Tb patients.

Original languageEnglish
Pages (from-to)128-136
Number of pages9
JournalTuberculosis and Respiratory Diseases
Volume52
Issue number2
Publication statusPublished - 2002 Jan 1
Externally publishedYes

Fingerprint

Multidrug-Resistant Tuberculosis
Ofloxacin
Pharmacokinetics
Fluoroquinolones
Emaciation
Prothionamide
Body Mass Index
Aminosalicylic Acid
Cycloserine
Kanamycin
Streptomycin
Pharmaceutical Preparations
Area Under Curve
High Pressure Liquid Chromatography
Urine

Keywords

  • BMI
  • MDR-Tb
  • Ofloxacin
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Park, S. K., Yoon, Y. R., Lee, W. C., Jun, H. M., Shon, J. H., Kim, K. A., ... Shin, J. G. (2002). Pharmacokinetics of ofloxacin in patients with multidrug-resistant tuberculosis. Tuberculosis and Respiratory Diseases, 52(2), 128-136.

Pharmacokinetics of ofloxacin in patients with multidrug-resistant tuberculosis. / Park, Seung Kyu; Yoon, Young Ran; Lee, Woo Chul; Jun, Hyung Min; Shon, Ji Hong; Kim, Kyoung Ah; Park, Ji-Young; Shin, Jae Gook.

In: Tuberculosis and Respiratory Diseases, Vol. 52, No. 2, 01.01.2002, p. 128-136.

Research output: Contribution to journalArticle

Park, SK, Yoon, YR, Lee, WC, Jun, HM, Shon, JH, Kim, KA, Park, J-Y & Shin, JG 2002, 'Pharmacokinetics of ofloxacin in patients with multidrug-resistant tuberculosis', Tuberculosis and Respiratory Diseases, vol. 52, no. 2, pp. 128-136.
Park SK, Yoon YR, Lee WC, Jun HM, Shon JH, Kim KA et al. Pharmacokinetics of ofloxacin in patients with multidrug-resistant tuberculosis. Tuberculosis and Respiratory Diseases. 2002 Jan 1;52(2):128-136.
Park, Seung Kyu ; Yoon, Young Ran ; Lee, Woo Chul ; Jun, Hyung Min ; Shon, Ji Hong ; Kim, Kyoung Ah ; Park, Ji-Young ; Shin, Jae Gook. / Pharmacokinetics of ofloxacin in patients with multidrug-resistant tuberculosis. In: Tuberculosis and Respiratory Diseases. 2002 ; Vol. 52, No. 2. pp. 128-136.
@article{b93e63f057f44121a09a0fa1f7716ebf,
title = "Pharmacokinetics of ofloxacin in patients with multidrug-resistant tuberculosis",
abstract = "Background: There are few studies that have reported on the pharmacokinetic(PK) disposition of fluoroquinolones in patients with multi-drug resistant tuberculosis (MDR-Tb), even though fluoroquinolones are frequently co-prescribed to those patients. In this study, the PK disposition of ofloxacin, a fluoroquinolone, was evaluated in patients with MDR-Tb. Methods: Twenty patients with MDR-Tb were given 2nd line Tb drugs including ofloxacin (300mg twice a day), prothionamide, cycloserine, para-aminosalicylic acid, kanamycin, and streptomycin. The patients were grouped according to their body mass index(BMI) as an index of emaciation (group A: 18.5≤BMI<23, group B: BMI<18.5). Blood samples were serially drawn and urine samples were collected upto 24 hours after the last dose of those drugs at steady state (over 1 month). The ofloxacin concentrations were determined using HPLC (High Performance Liquid Chromatography). Results: The AUC of ofloxacin in group B was greater than that in group A (31.4±8.9μg/ml·h vs. 24.1± 6.2μg/ml·h) (Check the symbols), (p<0.05). The total clearance (Cl/F) of ofloxacin was 0.16±0.03 L/h/kg in group A, and 0.14±0.03 L/h/kg in group B. The half-lives of ofloxacin in two groups were similar (group A: 5.3±0.8 hours, group B: 5.7±0.9 hours). In addition, the other PK parameters in two groups were also similar. Conclusions: The pharmacokinetics of ofloxacin in patients with MDR-Tb appears to be comparable with those of normal subjects, and the extent of emaciation appears to have an influence on the pharmacokinetics of ofloxaicn in chronic debilitated MDR-Tb patients.",
keywords = "BMI, MDR-Tb, Ofloxacin, Pharmacokinetics",
author = "Park, {Seung Kyu} and Yoon, {Young Ran} and Lee, {Woo Chul} and Jun, {Hyung Min} and Shon, {Ji Hong} and Kim, {Kyoung Ah} and Ji-Young Park and Shin, {Jae Gook}",
year = "2002",
month = "1",
day = "1",
language = "English",
volume = "52",
pages = "128--136",
journal = "Tuberculosis and Respiratory Diseases",
issn = "1738-3536",
publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of ofloxacin in patients with multidrug-resistant tuberculosis

AU - Park, Seung Kyu

AU - Yoon, Young Ran

AU - Lee, Woo Chul

AU - Jun, Hyung Min

AU - Shon, Ji Hong

AU - Kim, Kyoung Ah

AU - Park, Ji-Young

AU - Shin, Jae Gook

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Background: There are few studies that have reported on the pharmacokinetic(PK) disposition of fluoroquinolones in patients with multi-drug resistant tuberculosis (MDR-Tb), even though fluoroquinolones are frequently co-prescribed to those patients. In this study, the PK disposition of ofloxacin, a fluoroquinolone, was evaluated in patients with MDR-Tb. Methods: Twenty patients with MDR-Tb were given 2nd line Tb drugs including ofloxacin (300mg twice a day), prothionamide, cycloserine, para-aminosalicylic acid, kanamycin, and streptomycin. The patients were grouped according to their body mass index(BMI) as an index of emaciation (group A: 18.5≤BMI<23, group B: BMI<18.5). Blood samples were serially drawn and urine samples were collected upto 24 hours after the last dose of those drugs at steady state (over 1 month). The ofloxacin concentrations were determined using HPLC (High Performance Liquid Chromatography). Results: The AUC of ofloxacin in group B was greater than that in group A (31.4±8.9μg/ml·h vs. 24.1± 6.2μg/ml·h) (Check the symbols), (p<0.05). The total clearance (Cl/F) of ofloxacin was 0.16±0.03 L/h/kg in group A, and 0.14±0.03 L/h/kg in group B. The half-lives of ofloxacin in two groups were similar (group A: 5.3±0.8 hours, group B: 5.7±0.9 hours). In addition, the other PK parameters in two groups were also similar. Conclusions: The pharmacokinetics of ofloxacin in patients with MDR-Tb appears to be comparable with those of normal subjects, and the extent of emaciation appears to have an influence on the pharmacokinetics of ofloxaicn in chronic debilitated MDR-Tb patients.

AB - Background: There are few studies that have reported on the pharmacokinetic(PK) disposition of fluoroquinolones in patients with multi-drug resistant tuberculosis (MDR-Tb), even though fluoroquinolones are frequently co-prescribed to those patients. In this study, the PK disposition of ofloxacin, a fluoroquinolone, was evaluated in patients with MDR-Tb. Methods: Twenty patients with MDR-Tb were given 2nd line Tb drugs including ofloxacin (300mg twice a day), prothionamide, cycloserine, para-aminosalicylic acid, kanamycin, and streptomycin. The patients were grouped according to their body mass index(BMI) as an index of emaciation (group A: 18.5≤BMI<23, group B: BMI<18.5). Blood samples were serially drawn and urine samples were collected upto 24 hours after the last dose of those drugs at steady state (over 1 month). The ofloxacin concentrations were determined using HPLC (High Performance Liquid Chromatography). Results: The AUC of ofloxacin in group B was greater than that in group A (31.4±8.9μg/ml·h vs. 24.1± 6.2μg/ml·h) (Check the symbols), (p<0.05). The total clearance (Cl/F) of ofloxacin was 0.16±0.03 L/h/kg in group A, and 0.14±0.03 L/h/kg in group B. The half-lives of ofloxacin in two groups were similar (group A: 5.3±0.8 hours, group B: 5.7±0.9 hours). In addition, the other PK parameters in two groups were also similar. Conclusions: The pharmacokinetics of ofloxacin in patients with MDR-Tb appears to be comparable with those of normal subjects, and the extent of emaciation appears to have an influence on the pharmacokinetics of ofloxaicn in chronic debilitated MDR-Tb patients.

KW - BMI

KW - MDR-Tb

KW - Ofloxacin

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0036111177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036111177&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 128

EP - 136

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

SN - 1738-3536

IS - 2

ER -